Article
Genetic correction of serum AFP level improves risk prediction of primary hepatocellular carcinoma in the Dongfeng-Tongji cohort study.
Cancer medicine - 1 Jun 2018
Wang Ke, Bai Yansen, Chen Shi, Huang Jiao, Yuan Jing, Chen Weihong, Yao Ping, Miao Xiaoping, Wang Youjie, Liang Yuan, Zhang Xiaomin, He Meian, Yang Handong, Guo Huan, Wei Sheng
Abstract excerpt
Serum alpha-fetoprotein (AFP) is the most commonly used tumor biomarker for screening and diagnosis of primary hepatocellular carcinoma (HCC). However, the predictive effect for HCC risk is still unsatisfactory. The aim of this prospective study was to estimate whether the individual genetic correction could improve the prediction efficiency of AFP for HCC risk. A prospective analysis with 9819 baseline HCC-free...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
